His Bundle Pacing in Bradycardia and Heart Failure
Launched by YONG-MEI CHA · Dec 30, 2016
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at different types of heart pacing treatments for patients with bradycardia (a slow heart rate) and heart failure. The study will involve participants who need a pacemaker or other devices to help manage their heart conditions. Researchers want to understand how two specific types of pacing, called His bundle pacing and left bundle area pacing, affect the way electrical signals move through the heart. This information could help improve treatment for patients with heart failure or heart rhythm problems.
To be eligible for this trial, participants should be between the ages of 65 and 74, and they may have heart failure or specific types of heart block or slow heart rates that require a pacemaker. During the study, participants can expect to have additional heart rhythm measurements taken while their pacemaker is being implanted. This trial is currently recruiting participants, and it's important to note that individuals under 18 years old or those who are pregnant cannot take part.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • HF Group
- • Clinically recommended to undergo PM, CRT-P, or CRT-D implantation or HIBP/LBAP (including HIBP/LBAP for patients with HF, for patients who have failed CRT implant or patients who are CRT non-responders)
- • Any QRS duration
- • LVEF ≤ 50%
- • AV Block/Bradycardia Group
- • Recommended to undergo dual chamber pacemaker implantation
- • Any AV block or Sinus Bradycardia
- Exclusion Criteria:
- • Age \< 18 years
- • Pregnant
About Yong Mei Cha
Yong-Mei Cha is a dedicated clinical trial sponsor focused on advancing medical research and innovation through rigorous study design and execution. With a commitment to improving patient outcomes, the organization collaborates with healthcare professionals and researchers to conduct high-quality clinical trials across various therapeutic areas. Yong-Mei Cha emphasizes ethical practices and regulatory compliance, ensuring the safety and well-being of participants while striving to bring cutting-edge therapies to market. Through their expertise and passion for science, they aim to contribute significantly to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Patients applied
Trial Officials
Yong-Mei Cha, M.D.
Principal Investigator
Mayo Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials